Novo Nordisk Beat Expectations in Q4 and a Huge Catalyst Could Be Coming Soon
Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...
Is Novo Nordisk A/S (NVO) the Best Foreign Dividend Stock to Buy According to Analysts?
We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. In this article, we are ...
13 Best Foreign Dividend Stocks To Buy According to Analysts
In this article, we discuss 13 Best Foreign Dividend Stocks To Buy According to Analysts.
Novo Nordisk A/S (NVO): Among the Best International Dividend Stocks to Buy Now
We recently compiled a list of the 12 Best International Dividend Stocks To Buy Now. In this article, we are going to take a ...
BioSpace3d
Lilly Signs Back-to-Back Deals in MASH, Cancer
Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...
Ozempic competitors show there’s much to gain in weight loss drugs
Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment.
stockhead4d
Ozempic’s PBS push could shake up ASX food stocks, and here’s how
Big pharma’s pushing for PBS funding, and it’s kickstarting a shift to healthier snacks, smaller portions, and more ...
Experts warn of possible link between weight loss drugs and vision loss
Medical experts have raised concerns over popular weight loss drugs like Ozempic and Mounjaro after emerging evidence found they may lead to severe, and sometimes permanent, vision loss.
Mountaineering is meditation, says local Ozempic exec
The higher he climbs, the less he thinks about daily life, says Novo Nordisk’s Cem Ozenc. There’s no time when the mental and ...
Big pharma steps up push for taxpayer-funded weight-loss drugs
Novo Nordisk and Eli Lilly have used submissions to the federal government’s budget process to argue reducing obesity will be ...